<p>Prime Medicine, Inc. (NYSE:PRME - 获取免费报告) 的股价在周一交易中下跌了 7.2%。该股最低交易价为$3.52，最后交易价为$3.5450。在交易中，共成交了 1,344,568 股，较平均交易量 2,896,184 股下降了 54%。该股此前收盘价为$3.82。</p>
<p>获取 <strong>Prime Medicine</strong> 相关提醒：</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>2 只基因编辑股票值得在 2024 年关注</li>
</ul>
<p>多家券商对 PRME 进行了评估。Chardan Capital 将 Prime Medicine 的目标价从$10.00 下调至$9.00，并在 11 月 10 日的研究报告中给予该股 “买入” 评级。花旗集团将 Prime Medicine 的目标价从$5.00 下调至$4.25，并在 11 月 11 日的报告中给予该股 “中性” 评级。最后，Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并将 Prime Medicine 的目标价设定为$8.00。一位研究分析师给予该股 “强烈买入” 评级，四位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$9.21。</p>
<p><strong>阅读我们关于 PRME 的最新研究报告</strong></p>
<h2>Prime Medicine 价格表现</h2>
<p>该股的 50 日移动平均价格为$4.86，200 日移动平均价格为$3.70。该公司的市值为 6.4352 亿美元，市盈率为-1.74，贝塔值为 2.64。</p>
<h2>对 Prime Medicine 的对冲基金看法</h2>
<p>多家大型投资者最近调整了对 PRME 的持股。Creative Planning 在第二季度新购入了 Prime Medicine 的股份，价值$25,000。Freedom Investment Management Inc.在第二季度购买了 Prime Medicine 的新股份，价值$26,000。R Squared Ltd 在第二季度新购入了 Prime Medicine 的股份，价值$31,000。JTC Employer Solutions Trustee Ltd 在第二季度新购入了 Prime Medicine 的股份，价值$33,000。最后，Savant Capital LLC 在第二季度新购入了 Prime Medicine 的股份，价值约$37,000。目前，70.37% 的股票由机构投资者和对冲基金持有。</p>
<h2>Prime Medicine 公司简介</h2>
<p>(获取免费报告)</p>
<p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含一个 Prime Editor 蛋白质，由 Cas 蛋白和逆转录酶融合而成；以及一个 pegRNA，旨在将 Prime Editor 定位到特定基因组位置，并提供制作目标 DNA 序列所需编辑的模板。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>投资者需要了解的击败市场的信息</li>
<li>如果 D-Wave 风险太大，请考虑这 3 只量子 ETF 进行多元化</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>NVIDIA 的 13F 揭示了 2 个第三季度赢家——以及 1 个痛苦的失误</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>为什么银在 2025 年胜过黄金和标准普尔——接下来会发生什么</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Prime Medicine 吗？</h2>
<p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRME

<p>Prime Medicine 的股票（纽约证券交易所代码：PRME）下跌了 7.2%，至 3.5450 美元，交易量较平均水平下降了 54%。分析师调整了目标价格：Chardan Capital 为 9.00 美元，花旗集团为 4.25 美元，Wedbush 为 8.00 美元。该股票的共识评级为 “适度买入”，平均目标价格为 9.21 美元。机构投资者持有 70.37% 的股份。Prime Medicine 专注于用于基因治疗的基因编辑技术</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report)'s share price fell 7.2% during trading on Monday . The stock traded as low as $3.52 and last traded at $3.5450. 1,344,568 shares changed hands during trading, a decline of 54% from the average session volume of 2,896,184 shares. The stock had previously closed at $3.82.</p>
<div class="lb-trans"><p>Prime Medicine, Inc. (NYSE:PRME - 获取免费报告) 的股价在周一交易中下跌了 7.2%。该股最低交易价为$3.52，最后交易价为$3.5450。在交易中，共成交了 1,344,568 股，较平均交易量 2,896,184 股下降了 54%。该股此前收盘价为$3.82。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 相关提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票值得在 2024 年关注</li>
</ul>
</div><p>A number of brokerages have weighed in on PRME. Chardan Capital lowered their price target on Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, November 10th. Citigroup lowered their target price on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Wedbush reiterated an &#34;outperform&#34; rating and set a $8.00 target price on shares of Prime Medicine in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $9.21.</p>
<div class="lb-trans"><p>多家券商对 PRME 进行了评估。Chardan Capital 将 Prime Medicine 的目标价从$10.00 下调至$9.00，并在 11 月 10 日的研究报告中给予该股 “买入” 评级。花旗集团将 Prime Medicine 的目标价从$5.00 下调至$4.25，并在 11 月 11 日的报告中给予该股 “中性” 评级。最后，Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 评级，并将 Prime Medicine 的目标价设定为$8.00。一位研究分析师给予该股 “强烈买入” 评级，四位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为$9.21。</p>
</div><p><strong>Read Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PRME 的最新研究报告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 价格表现</h2>
</div><p>The stock has a 50 day moving average price of $4.86 and a two-hundred day moving average price of $3.70. The company has a market capitalization of $643.52 million, a price-to-earnings ratio of -1.74 and a beta of 2.64.</p>
<div class="lb-trans"><p>该股的 50 日移动平均价格为$4.86，200 日移动平均价格为$3.70。该公司的市值为 6.4352 亿美元，市盈率为-1.74，贝塔值为 2.64。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>对 Prime Medicine 的对冲基金看法</h2>
</div><p>A number of large investors have recently modified their holdings of PRME. Creative Planning acquired a new position in Prime Medicine during the 2nd quarter worth $25,000. Freedom Investment Management Inc. bought a new stake in shares of Prime Medicine during the second quarter worth $26,000. R Squared Ltd acquired a new position in shares of Prime Medicine during the second quarter valued at $31,000. JTC Employer Solutions Trustee Ltd acquired a new position in shares of Prime Medicine during the second quarter valued at $33,000. Finally, Savant Capital LLC bought a new position in Prime Medicine in the second quarter valued at about $37,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家大型投资者最近调整了对 PRME 的持股。Creative Planning 在第二季度新购入了 Prime Medicine 的股份，价值$25,000。Freedom Investment Management Inc.在第二季度购买了 Prime Medicine 的新股份，价值$26,000。R Squared Ltd 在第二季度新购入了 Prime Medicine 的股份，价值$31,000。JTC Employer Solutions Trustee Ltd 在第二季度新购入了 Prime Medicine 的股份，价值$33,000。最后，Savant Capital LLC 在第二季度新购入了 Prime Medicine 的股份，价值约$37,000。目前，70.37% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含一个 Prime Editor 蛋白质，由 Cas 蛋白和逆转录酶融合而成；以及一个 pegRNA，旨在将 Prime Editor 定位到特定基因组位置，并提供制作目标 DNA 序列所需编辑的模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>If D-Wave Is Too Risky, Consider These 3 Quantum ETFs for Diversification</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>NVIDIA’s 13F Reveals 2 Q3 Winners—And 1 Painful Miss</li>
<li>3 Best Fintech Stocks for a Portfolio Boost</li>
<li>Why Silver Beat Gold and the S&amp;P in 2025—And What Comes Next</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Prime Medicine</li>
<li>投资者需要了解的击败市场的信息</li>
<li>如果 D-Wave 风险太大，请考虑这 3 只量子 ETF 进行多元化</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>NVIDIA 的 13F 揭示了 2 个第三季度赢家——以及 1 个痛苦的失误</li>
<li>3 只最佳金融科技股票，助力投资组合提升</li>
<li>为什么银在 2025 年胜过黄金和标准普尔——接下来会发生什么</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Prime Medicine (NYSE:PRME) 的股价下跌了 7.2% - 以下是原因